|
|
| | 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester Basic information |
| | 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester Chemical Properties |
| Melting point | 161℃ | | Boiling point | 889.7±75.0 °C(Predicted) | | density | 1.18±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 13.18±0.29(Predicted) | | form | Solid | | color | White to Off-White | | Water Solubility | 4.6μg/L at 25℃ | | LogP | 9.64 at 25℃ |
| RIDADR | UN1325 | | HazardClass | 4.1 |
| | 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester Usage And Synthesis |
| Uses | Tritylolmesartan Ethyl Ester is an impurity of olmesartan medoxomil (O550000), an angiotensin II receptor antagonist and anti-hypertensive drug. | | Synthesis | To ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate (BIH, 100 g, 1 eq.) was added dichloromethane (500 mL, 5 vol.), and stirred until completely dissolved. Triethylamine (32.3 mL, 1.1 eq.) was added and the reaction mixture was cooled to 0 °C - 5 °C. A solution of triphenylchloromethane (63.22 g, 1.08 eq.) in dichloromethane (300 mL, 3 vol.) was slowly added dropwise over 30 min at 0 °C-5 °C. After the dropwise addition was completed, the reaction mixture was warmed to 25°C-30°C with continuous stirring for 12 hours. Triphenylchloromethane (2.92 g, 0.05 eq.) was added additionally and stirring was continued for 3 hours. The reaction was monitored by thin layer chromatography (TLC, unfolding agent: 10% methanol/dichloromethane, UV detection) to confirm complete conversion of BIH. The reaction mixture was cooled to 0°C-5°C, demineralized water (270 mL, 2.7 v/v) was added, and stirred at 25°C-30°C for 15 min. Layers were left to separate and the aqueous phase was extracted with dichloromethane (200 mL, 2 volumes). The organic phases were combined and washed with deionized water (500 mL, 5 volumes). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure at 40°C-45°C to afford ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-(triphenylmethyltetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate (BIT, 135 g, 89% yield). | | References | [1] Patent: EP2891650, 2015, A1. Location in patent: Paragraph 0298-0300 [2] Patent: US2015/239854, 2015, A1. Location in patent: Page/Page column 39 |
| | 1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester Preparation Products And Raw materials |
|